Enhancing PD-1 or CTLA-4 activity may weaken tumor immunosurveillance, particularly in patients with latent or undiagnosed malignancies, as forced PD-1 expression has been shown to promote tumor cell proliferation through SHP2–Ras–MAPK signaling [93]. This evidence concerns the gene PTPN11 and neoplasm.